Insider Trading Alert - NUVA, MNTA And AKR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 2, 2014, 108 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $4.00 to $2,890,477.87.

Highlighted Stocks Traded by Insiders:

NuVasive (NUVA) - FREE Research Report

Valentine Keith, who is Coo at NuVasive, sold 2,500 shares at $43.66 on Dec. 2, 2014. Following this transaction, the Coo owned 70,236 shares meaning that the stake was reduced by 3.44% with the 2,500-share transaction.

The shares most recently traded at $44.47, up $0.81, or 1.82% since the insider transaction. Historical insider transactions for NuVasive go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 71,242

The average volume for NuVasive has been 325,700 shares per day over the past 30 days. NuVasive has a market cap of $2.1 billion and is part of the health care sector and health services industry. Shares are up 33.81% year-to-date as of the close of trading on Monday.

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for the spine. Its products focus on applications for spine fusion surgery. Currently, there are 10 analysts who rate NuVasive a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUVA - FREE

TheStreet Quant Ratings rates NuVasive as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full NuVasive Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Shapiro Bennett M, who is Director at Momenta Pharmaceuticals, sold 9,903 shares at $12.00 on Dec. 2, 2014. Following this transaction, the Director owned 10,834 shares meaning that the stake was reduced by 47.76% with the 9,903-share transaction.

The shares most recently traded at $11.95, down $0.05, or 0.42% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 11,267
  • 12-Week # shares sold: 18,630
  • 24-Week # shares sold: 35,440

The average volume for Momenta Pharmaceuticals has been 470,200 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $622.3 million and is part of the health care sector and drugs industry. Shares are down 33.26% year-to-date as of the close of trading on Monday.

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Currently, there are 3 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Acadia Realty (AKR) - FREE Research Report

Braun Joel L, who is Executive Vice President at Acadia Realty, sold 3,720 shares at $31.69 on Dec. 2, 2014. Following this transaction, the Executive Vice President owned 26,135 shares meaning that the stake was reduced by 12.46% with the 3,720-share transaction.

The shares most recently traded at $31.68, down $0.01, or 0.05% since the insider transaction. Historical insider transactions for Acadia Realty go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 73,000

The average volume for Acadia Realty has been 354,300 shares per day over the past 30 days. Acadia Realty has a market cap of $2.1 billion and is part of the financial sector and real estate industry. Shares are up 27.51% year-to-date as of the close of trading on Monday.

Acadia Realty Trust, a real estate investment trust (REIT), engages primarily in the ownership, acquisition, redevelopment, and management of retail properties in the United States. The stock currently has a dividend yield of 3%. The company has a P/E ratio of 27.1. Currently, there are 3 analysts who rate Acadia Realty a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AKR - FREE

TheStreet Quant Ratings rates Acadia Realty as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Acadia Realty Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target